Possible applications for combined lenvatinib and pembrolizumab in advanced endometrial carcinoma
Endometrial cancer is one of the most common gynaecological cancers in both the United States and the Russian Federation, and the rate continues to rise. Although early-stage endometrial cancer is associated with a favourable 5-year survival rate (96%), this rate in patients with distant metastases...
Saved in:
Main Authors: | K. V. Menshikov, A. V. Sultanbaev, Sh. I. Musin, I. A. Menshikova, N. I. Sultanbaeva, A. A. Izmailov, A. A. Fatikhova, D. O. Lipatov, G. A. Serebrennikov |
---|---|
Format: | Article |
Language: | English |
Published: |
Bashkir State Medical University
2023-01-01
|
Series: | Креативная хирургия и онкология |
Subjects: | |
Online Access: | https://www.surgonco.ru/jour/article/view/738 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Lenvatinib and pembrolizumab in patients with advanced uterine cancer
by: A. G. Kedrova, et al.
Published: (2021-01-01) -
COMBINATION OF LENVATINIB AND PEMBROLISUMAB IN THE TREATMENT OF ADVANCED ENDOMETRIAL CANCER: A CASE REPORT
by: O. N. Churuksaeva, et al.
Published: (2021-03-01) -
Efficient sequence of therapy for advanced and metastatic endometrial cancer
by: A. A. Rumyantsev
Published: (2022-09-01) -
Combination of pembrolizumab and lenvatinib in second-line therapy for MSS/pMMR advanced endometrial cancer: literature review and a case report
by: A. D. Darenskaya, et al.
Published: (2024-01-01) -
Microsatellite instability in endometrial cancer: the role of diagnostic methods and their clinical application. Expert consensus
by: A. S. Tyulyandina, et al.
Published: (2023-05-01)